Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07333053 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Efficacy of Transarterial Infusion Chemotherapy for Unresectable Colorectal Cancer

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 1 of 1 changed
See other at-risk trials from Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Record History

See every version on ClinicalTrials.gov ↗

  1. Sponsor changed: Quanda Liu to Guang'anmen Hospital of China Academy of Chinese Medical Sciences
    • Collaborators revised (12)
    v5
  2. Primary endpoint(s) modifiedv4 Show 6 more changesShow less
    • Enrollment increased: 30 → 50 participants
    • Start date changed from estimate of Mar 31, 2026 to Mar 20, 2026
    • Eligibility criteria expanded, about 80 words
    • Secondary endpoints: 5 to 6
    • Study description expanded, about 604 words
    • Collaborators revised (12)
  3. Start date: Jan 31, 2026 to Mar 31, 2026
    • Secondary endpoints: details revised at 1 of 5 entries
    v3
  4. Primary endpoints: 2 to 1
    • Secondary endpoints: 9 to 5
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a prospective, multicenter, randomized, open-label clinical trial. It aims to investigate whether intensive transarterial infusion chemotherapy (TAIC) followed by sequential intravenous chemotherapy (IVC) is clinically more effective than IVC alone in the treatment of unresectable colorectal cancer (uCRC).
Trial Details
NCT Number NCT07333053
Lead Sponsor Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Collaborators: Liaoning Cancer Hospital & Institute, The Rocket Force Characteristic Medical Center, Second Affiliated Hospital of Nanchang University, Affiliated Hospital of Hebei University, The First Hospital of Qinhuangdao, The Central Hospital of Handan City, The First People's Hospital of Jiujiang City, Changzhi Medical College, Zibo Boshan District Traditional Chinese Medicine Hospital, Hebei Yixian Hospital, Baoding Mancheng District People's Hospital, The Shanghai Yangpu Central Hospital
Conditions
(from sponsor)		 Unresectable Colorectal Cancer
Related terms Colorectal Neoplasms
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov